RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells

被引:0
作者
Bo Lou
Kate Connor
Kieron Sweeney
Ian S. Miller
Alice O’Farrell
Eduardo Ruiz-Hernandez
David M. Murray
Garry P. Duffy
Alan Wolfe
Enrico Mastrobattista
Annette T. Byrne
Wim E. Hennink
机构
[1] Utrecht University,Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences
[2] Royal College of Surgeons in Ireland,Department of Physiology and Medical Physics
[3] Beaumont Hospital,Department of Neurosurgery
[4] School of Pharmacy and Pharmaceutical Sciences,Anatomy, School of Medicine, College of Medicine Nursing and Health Sciences
[5] Trinity College Dublin,undefined
[6] National University of Ireland,undefined
[7] UCD School of Veterinary Medicine,undefined
来源
Drug Delivery and Translational Research | 2019年 / 9卷
关键词
Cancer targeting; siRNA delivery; Glioblastoma; cRGD peptide; Cholesterol modification;
D O I
暂无
中图分类号
学科分类号
摘要
The development of an effective and safe treatment for glioblastoma (GBM) represents a significant challenge in oncology today. Downregulation of key mediators of cell signal transduction by RNA interference is considered a promising treatment strategy but requires efficient, intracellular delivery of siRNA into GBM tumor cells. Here, we describe novel polymeric siRNA nanocarriers functionalized with cRGD peptide that mediates targeted and efficient reporter gene silencing in U87R invasive human GBM cells. The polymer was synthesized via RAFT copolymerization of N-(2-hydroxypropyl)-methacrylamide (HPMA) and N-acryloxysuccinimide (NAS), followed by post-polymerization modification with cholesterol for stabilization, cationic amines for siRNA complexation, and azides for copper-free click chemistry. The novel resultant cationic polymer harboring a terminal cholesterol group, self-assembled with siRNA to yield nanosized polyplexes (~ 40 nm) with good colloidal stability at physiological ionic strength. Post-modification of the preformed polyplexes with PEG-cRGD end-functionalized with bicyclo[6.1.0]nonyne (BCN) group resulted in enhanced cell uptake and increased luciferase gene silencing in U87R cells, compared to polyplexes lacking cRGD-targeting groups.
引用
收藏
页码:679 / 693
页数:14
相关论文
共 350 条
  • [11] Stupp R(2010)Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers Biomacromolecules. 11 505-514
  • [12] Mason W(2010)HPMA copolymers: origins, early developments, present, and future Adv Drug Deliv Rev 62 122-149
  • [13] van den Bent MJ(2010)HPMA copolymers: 30 years of advances Adv Drug Deliv Rev 62 119-121
  • [14] Weller M(2004)Polymer side-chain degradation as a tool to control the destabilization of polyplexes Pharm Res 21 170-176
  • [15] Fisher BM(2008)Biodegradable, cationic methacrylamide-based polymers for gene delivery to ovarian cancer cells in mice Mol Pharm 5 349-357
  • [16] Taphoorn MJB(2012)Cationic polymers and their therapeutic potential Chem Soc Rev 41 7147-7194
  • [17] Belanger K(2016)Polymers for siRNA delivery: a critical assessment of current technology prospects for clinical application ACS Biomater Sci Eng 2 1837-1850
  • [18] Brandes AA(2012)Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers J Control Release 161 554-565
  • [19] Marosi C(2016)PEGylation as a strategy for improving nanoparticle-based drug and gene delivery Adv Drug Deliv Rev 99 28-51
  • [20] Bogdahn U(2011)Effect of integrin targeting and PEG shielding on polyplex micelle internalization studied by live-cell imaging J Control Release 156 364-373